The ophthalmologist and the global impact of the AIDS epidemic: LV Edward Jackson Memorial Lecture

American Journal of Ophthalmology

Volumn 129, Issue 1, 2000, Pages 1-8

  Belfort Jr , Rubens ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIVIRUS AGENT; FOSCARNET; GANCICLOVIR; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DEVELOPING COUNTRY; EPIDEMIC; EYE INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; OPHTHALMOLOGY; PRIORITY JOURNAL; RETINITIS; SOCIOECONOMICS;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; EYE INFECTIONS, VIRAL; HUMANS; OPHTHALMOLOGY; SOCIOECONOMIC FACTORS; WORLD HEALTH;

EID: 0343485127     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9394(99)00428-6     Document Type: Conference Paper

References (82)

1. Lichter P.R. Honoring the history of the Edward Jackson Memorial Lecture the L Edward Jackson Memorial Lecture. Part 1 . Am J Ophthalmol. 117:1994;699-705.
2. Albert D.M. Edward Jackson in 1986 a man and his specialty at a crossroads: LIII Edward Jackson Memorial Lecture: Part 1 . Am J Ophthalmol. 122:1996;469-475.
3. Cunningham E.T. Jr, Margolis T.P. Ocular manifestations of HIV infection. N Engl J Med. 339:1998;236-244.
4. Jabs D.A., Quinn T.C. Acquired immunodeficiency syndrome. Pepose J.S., Holland G.N., Wilhelmus K.R. Ocular infection and immunity. 1996;289-310 Mosby, St Louis.
5. Forrester J.V., Okada A.A., BenEzra D., Ohno S. Posterior segment intraocular inflammation guidelines . 1998;1-184 Kugler Publications, The Hague, The Netherlands.
6. Pneumocystis pneumonia - Los Angeles, MMWR Morbid Mortal Wkly Rep. 30:1981;250.
7. Pietermaritzburg H.K. AIDS in the third world a global disaster . Economist. 1999;42-44.
8. Holland G.N., Gottlieb M.S., Yee R.D., Schanker H.M., Petti T.H. Ocular disorders associated with a new severe acquired cellular immunodeficiency syndrome. Am J Ophthalmol. 93:1982;393-402.
9. Gallo R.C., Salahuddin S.Z., Popovic M., et al. Frequent detection and isolation of cytopathic retroviruses (HTLV III) from patients with AIDS and risk for AIDS. Science. 224:1984;500.
10. Fischl M.A., Richman D.D., Hansen N., et al. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection a double-blind, placebo-controlled trial . Ann Intern Med. 112:1990;727-737.
11. United States Food and Drug Administration. Approved therapies for HIV/AIDS or AIDS-related conditions. URL: http://www.verity.FDA-GOV/search 97 cgi/s97.10, October 1998.
12. Mellors J.W. Viral-load tests provide valuable answers. Sci Am. 279:1998;70-73.
13. Volberding P.A. HIV/AIDS protease inhibitors vindicated . Lancet. 350:1997;10-11.
14. Palella F.J. Jr, Delaney K.M., Moorman A.C., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 338:1998;853-860.
15. Gulik R., Mellors J., Havlir D., et al. Treatment with indinavir, zidovudine, and lamivudine, in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 377:1997;734-739.
16. Hammer S., Squires K., Hughes M., et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 337:1997;725-733.
17. Whitcup S.M., Fortin E., Nussenblatt R.B., Polis M.A., Muccioli C., Belfort R. Jr. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA. 277:1997;1519-1520.
18. Volberding P.A., Deeks S.G. Antiretroviral therapy for HIV infection promises and problems . JAMA. 279:1998;1343-1344.
19. Powderly W.G., Landay A., Lederman M.M. Recovery of the immune system with antiretroviral therapy. JAMA. 280:1998;72-77.
20. Tural C., Romeu J., Sirera G., et al. Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients. J Infect Dis. 177:1998;1080-1083.
21. Pakker N.G., Notermans D.W., de Boer R.J., et al. Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection. Nat Med. 4:1998;208-214.
22. Bartlett J.G., Moore R.D. Improving HIV therapy. Sci Am. 279:1998;64-67.
23. Richman D.D. How drug resistance arises. Sci Am. 279:1998;68-69.
24. Hirschel B., Francioli P. Progress and problems in the fight against AIDS. [editorial] N Engl J Med. 338:1998;13.
25. Hecht FM, Colfax G, Swanson M, Chesney MA. Adherence and effectiveness of protease inhibitors in clinical practice. In: Program and abstracts of the fifth conference on retroviruses and opportunistic infections; February 1-5, 1998, Chicago, Illinois. Abstract 151/Session 24. URL: http://www.retroconference.org (accessed March 26, 1998).
26. Lo J.C., Mulligan K., Tai W.W., Algren H., Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 351:1998;867-870.
27. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351:1998;1881-1883.
28. AIDS, the unbridgeable gap. Lancet 1997;351:1825.
29. Powderly W.G., Landay A., Lederman M.M. Recovery of the immune system with antiretroviral therapy. JAMA. 280:1998;72-77.
30. Mouton Y., Cartier F., Dellamonica P., et al. Dramatic cut in AIDS defining events hospitalization for patients under protease inhibitors (PI) and tritherapies (TTT) in 9 AIDS reference centers (ARC) and 7,391 patients program and abstracts of the fourth conference on retroviruses and opportunistic infections . N Engl J Med. 208:1999;22-26.
31. Guembel H.O.C., Ohrloff C. Opportunistic infections of the eye in immunocompromised patients. Ophthalmologica. 211:1997;53-61.
32. Holland G.N., Tufail A., Jordan M.C. Cytomegalovirus diseases. Pepose J.S., Holland G.N., Wilhelmus K.R. Ocular infection and immunity. 1996;1088-1129 Mosby, St Louis.
33. Holland G.N., O'Connor G.R., Belfort R. Jr, Remington J.S. Toxoplasmosis. Pepose J.S., Holland G.N., Wilhelmus K.R. Ocular infection and immunity. 1996;1183-1223 Mosby, St Louis.
34. Culbertson W.W., Dix R.D. Vancella-zoster virus diseases posterior segment of the eye . Pepose J.S., Holland G.N., Wilhelmus K.R. Ocular infection and immunity. 1996;1131-1154 Mosby, St Louis.
35. Recommendations for prevention of HIV transmission in health care settings. MMWR Morbid Mortal Wkly Rep. 36:(suppl 2):1987;35-185.
36. Buchbinder S. Avoiding infection after HIV exposure. Sci Am. 1998;84-85.
37. Whitcup S.M., Butler K.M., Caruso R., et al. Retinal toxicity in children treated with 2′,3′-dideoxyinosine. Am J Ophthalmol. 113:1992;1-7.
38. Lewallen S., Courtright P. HIV and AIDS and the eye in developing countries. Arch Ophthalmol. 115:1997;1291-1295.
39. Belfort R., de Smet M., Whitcup S.M., et al. Ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with AIDS. Cornea. 10:1991;536-538.
40. Muccioli C., Petri V., Belfort R. Jr. Acquired immunodeficiency syndrome ophthalmic and dermatologic manifestations . Mannis M.J., Macsai M.S., Huntley A.C. Eye and skin disease. 1996;471-487 Lippincott-Raven, Philadelphia.
41. Cunningham E.T. Jr, Margolis T.P. Ocular manifestations of HIV infection. N Engl J Med. 339:1998;236-244.
42. Barnes P.F., Block A.B., Davidson P.T., et al. Tuberculosis in patients with human immunodeficiency virus infection. N Engl J Med. 324:1991;1644-1650.
43. Del Amo J., Petruckevitch A., Phillips A., et al. Spectrum of disease in Africans with AIDS in London. AIDS. 10:1996;1563-1569.
44. Misra S.N., Sengupta D., Satpathy S.K. AIDS in India recent trends in opportunistic infections . Southeast Asian J Trop Med Public Health. 29:1998;373-376.
45. DeCock K.M., Gnaore E., Adjorlolo G., et al. Risk of tuberculosis in patients with HIV-I and HIV-II infections in Abidjan, Ivory Coast. BMJ. 302:1991;496-499.
46. Yoser S.L., Forster D.J., Rao N. Systemic viral infections and their retinal and choroidal manifestations. Surv Ophthalmol. 37:1993;313-352.
47. Muccioli C., Belfort R. Jr, Burnier M., Rao N. Squamous cell carcinoma of the conjunctiva in a patient with the acquired immunodeficiency syndrome. Am J Ophthalmol. 121:1996;94-96.
48. Ateenyi-Agaba C. Conjunctival squamous cell carcinoma associated with HIV infection in Kampala, Uganda. Lancet. 345:1995;695-696.
49. Lewallen S., Courtright P. HIV and AIDS and the eye in developing countries a review . Arch Ophthalmol. 115:1997;1291-1295.
50. Kaimbo W., Kaimbo D., Parys-Van Ginderdeuren R., Missotten L. Conjunctival squamous cell carcinoma and intraepithelial neoplasia in AIDS patients in Congo Kinshasa. Bull Soc Belge Ophthalmol. 268:1998;135-141.
51. Muccioli C., Belfort R. Jr, Lottenberg C., et al. Achados Oftalmológicos em AIDS avaliação de 445 casos atendidos em 1 ano . Rev Associacao Medica Brasileria. 40:1994;156-158.
52. Pertel P., Hirschtick R., Phair J., Chmiel J., Poggensee L., Murphy R. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr Hum Retrovirol. 5:1992;1069-1074.
53. Nelson M.R., Erskine D., Hawkins D.A., Gazzard G. Treatment with corticosteroids a risk factor for the development of clinical cytomegalovirus in AIDS . AIDS. 7:1993;375-378.
54. Karavellas M.P., Lowder C.Y., Macdonald C., Avila C.P. Jr, Freeman W.R. Immune recovery vitritis associated with inactive cytomegalovirus retinitis a new syndrome . Arch Ophthalmol. 116:1998;169-175.
55. Whitley R.J., Jacobson M.A., Friedberg D.N., et al. Guidelines for the treatment of cytomegalovirus diseases in patients with aids in the era of potent antiretroviral therapy. Arch Intern Med. 158:1998;957-969.
56. Mann J.M., Tarantola D.J.M. HIV 1998 the global picture . Sci Am. 279:1998;62-63.
57. Pollis M.A., Masur H. Promising new treatments for cytomegalovirus retinitis. JAMA. 273:1995;1457-1459.
58. Marx J.L., Kapusta M.A., Patel S.S., et al. Use of the ganciclovir implant in the treatment of recurrent cytomegalovirus retinitis. Arch Ophthalmol. 114:1996;815-820.
59. Marwick C. First "antisense" drug will treat CMV retinitis. JAMA. 280:1998;871.
60. Lewallen S. Ocular manifestations of the human immunodeficiency virus and the acquired immunodeficiency syndrome in developing countries. [letter] Arch Ophthalmol. 115:1997;435.
61. Cocherean-Massin I., Le Hoang P., Lautier-Fran M., et al. Ocular toxoplasmosis in human immunodeficiency virus-infected patients. Am J Ophthalmol. 114:1992;130-135.
62. Nussenblatt R.B., Belfort R. Jr. Ocular toxoplasmosis an old disease revisited . JAMA. 271:1994;304-307.
63. Zegans M.E., Walton R.C., Holland G.N., O'Donnell J.J., Jacobson M.A., Margolis T.P. Transient vitreous inflammatory reactions associated with combination antiretroviral therapy in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. 125:1998;292-300.
64. Canzano J.C., Reed J.B., Morse L.S. Vitreo macular traction syndrome follow highly active antiretroviral therapy in AIDS patients with cytomegalovirus retinitis. Retina. 18:1998;443-447.
65. Silverstein B.E., Smith J.H., Sykes S.O., Jones M.R., Schwartz D., Cunningham E.T. Jr. Cystoid macular edema associated with cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. Am J Ophthalmol. 125:1998;411-415.
66. Farah M.E., Muccioli C., Rinkevicius M., Lima L.B., Belfort R. Jr. Cystoid macular edema in patients with acquired immune deficiency syndrome and cytomegalovirus retinitis. Arq Bras Oftal. 61:1998;506.
67. Confronting AIDS: public priorities in a global epidemic. A World Bank policy research report 1997. New York: Oxford University Press, 1997:1-353.
68. Cardoso R. "Bridging the gap": opening ceremony from the 12th World AIDS Conference, 1998. URL: http://www.webcast.AIDS 98.org/sun 28jun sum.htm.
69. Piot P. "Bridging the gap": opening ceremony from the 12th World AIDS Conference, 1998. URL: http://www.webcast.AIDS 98.org/sun 28jun sum.htm.
70. Veeken H. Russia sex, drugs, and AIDS and MSF . BMJ. 316:1998;138-139.
71. Carael M., Schwartlander 3, Zewdre D. Demografic impact of AIDS. AIDS. 12:(suppl):1998;S1-S2.
72. Baltimore D., Heilman C. HIV vaccines prospects and challenges . Sci Am. 279:1998;78-83.
73. Gostin L.O., Lazzarini Z. AIDS and rights. JAMA. 279:1998;1121-1122.
74. Coates T.J., Collins C. Preventing HIV Infection. Sci Am. 279:1998;76-77.
75. Guttmacher S., Lieberman L., Ward D., Freudenberg N., Radosh A., Jarlais D.D. Condom availability in New York City Public High Schools relationships to condom use and sexual behavior . Am J Public Health. 87:1997;1427-1433.
76. Haburchak D.R. The economics of AIDS in America. AIDS Reader. 7:1997;155-160.
77. Becker S. The economics of AIDS and cost effective antiretroviral therapy. Clinical care options for HIV. Medscape HIV/AIDS 3(3), 1997. www.medscape.com.
78. Bozzette A.S., Berry S.H., Duan N., et al. The care of HIV-infected adults in the United States. N Engl J Med. 339:1998;1897-1904.
79. Panz V.R., Joffe B.I. Impact of HIV infection and AIDS on prevalence of type 2 diabetes in South Africa in 2010. [letter]. BMJ. 318:1999;1351.
80. Montaner J.S.G., Hogg R.S., Weber A.E., Anis A.H., Odshaughnessy M.V., Schechter M.T. The costs of triple-drug anti-HIV therapy in the Americas. JAMA. 279:1998;1263-1264.
81. Kasper T. Global patent police block cost-reduction efforts [letter]. Gay Men's Health Crisis. Treatment issues. Newsletter Exp AIDS Ther 1999;13:1.
82. Beardsley T. Coping with HIV's ethical dilemmas. Sci Am. 279:1998;86-87.